Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

October 13, 2023

Study Completion Date

February 6, 2024

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Nivolumab

480mg

DRUG

Nivolumab

240mg

DRUG

Ipilimumab

1mg/kg

Trial Locations (12)

17033

Penn State Cancer Institute, Hershey

21287

Johns Hopkins Sidney Kimmel Comprehensive, Baltimore

40202

University of Louisville James Graham Brown Cancer Center, Louisville

46202

Indiana University, Indianapolis

48201

Karmanos Cancer Center (Wayne State University), Detroit

48910

Michigan State University, Lansing

53705

University of Wisconsin, Madison

55455

University of Minnesota, Minneapolis

60612

Rush University Medical Center, Chicago

University of Illinois Cancer Center, Chicago

68198

University of Nebraska Medical Center, Omaha

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Big Ten Cancer Research Consortium

OTHER

lead

Greg Durm, MD

OTHER